Advances in Adoptive Cell Therapies

Originally aired on July 16, 2020

Cancer immunotherapies have revolutionized the way cancers are treated and have gained much traction in both pre-clinical and clinical research. Adoptive cell therapies (ACTs) involve the use of immune cells as anti-cancer agents and hold promise for the treatment of adult and pediatric cancer, ranging from liquid to solid tumors. One type of ACT involves chimeric antigen receptor (CAR)-engineered immune cells, with two CAR T-cell-based therapies recently approved by the FDA, paving the way for the development of additional ACT therapies.

In this webinar, leaders in the field of CAR-based adoptive cell therapies, Katy Rezvani, Robbie Majzner, and Marco Ruella, will discuss the current challenges and advances in the development of these anti-cancer therapies and their clinical impact.

Katy Rezvani
Professor, Department of Stem Cell Transplantation, MD Anderson Cancer Center;
Sally Cooper Murray Endowed Chair in Cancer Research;
Director of Translational Research, Department of Stem Cell Transplantation – Research, MD Anderson Cancer Center;
Medical Director, GMP and Cell Therapy Facility
View Biography
Marco Ruella
Assistant Professor of Medicine;
Scientific Director, Lymphoma Program;
Department: Medicine, University of Pennsylvania
View Biography
Robbie Majzner
Assistant Professor of Pediatrics in the Division of Hematology and Oncology, Stanford University

View Biography
Moderator: Montserrat (Montse) Rojo de la Vega
Scientific Editor, Cancer Cell

Registration Details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) denotes required form field(s)